Josh Rademacher

The leader of MaxHealth’s mergers and acquisition strategy, Joshua Rademacher, guides the organization’s inorganic growth activity in Florida and beyond. Over the last 17 years, Josh has worked in the senior most leadership positions across the healthcare spectrum including healthcare and pharmaceutical services with a focus on value-based care strategies. His experience allows him to deeply understand the various parts of what we do at MaxHealth and how best to position our activities to help deliver optimal value and outcomes for our patients, health plans, providers, and the broader communities we serve.

Josh is on numerous boards today and previously held the following positions:

• Chief Development Officer – The Oncology Institute
• Chief Executive Officer – 503B / 503A OptumRx
• Executive Vice President of Corporate Development & Strategy – Avella SRx
• General Manager Corporate Development – QuadMed
• Executive Vice President of Corporate Development & Strategy – Oncology Plus
• Chief of Staff – Oncology Therapeutics Network
• Associate – Madison Capital Funding
• Analyst – Lazard Middle-Market